Blue California successfully completes groundbreaking human clinical trial of ergothioneine.
Blue California completes groundbreaking human clinical trial on ErgoActive® ergothioneine intervention for cognitive function, memory, and sleep
05 févr. 2024 04h00 HE | Blue California Ingredients
Rancho Santa Margarita, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Blue California, an industry leader in science-driven ingredient development, announced the successful completion of a...
Axsome Logo.png
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting
07 déc. 2022 07h00 HE | Axsome Therapeutics, Inc.
Improvement in cognitive and physical functioning, measured by the CPFQ patient-rated scale, starting at week 1 and sustained over 12 months Improvement in disability, measured by the SDS, starting...
Healthy Extracts Introduces Breakthrough Nutraceutical Formulation, Ultimate Brain Nutrients ACTIVATE™, Clinically Proven to Enhance Key Brain Activity by 46%
08 juil. 2021 08h31 HE | Healthy Extracts Inc
LAS VEGAS, July 08, 2021 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a leading developer and manufacturer of science-forward, clinically proven, plant-based products for heart and brain...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy
03 déc. 2019 06h00 HE | Axsome Therapeutics, Inc.
Demonstrated statistically significant reduction in cataplexy attacks compared to placebo (p<0.001 on primary endpoint) Reduced excessive daytime sleepiness compared to placebo (p=0.003 on ESS;...
EC logo 400x400.jpg
Elemental Cognition Adds Three Notable Advisors
10 oct. 2019 07h00 HE | Elemental Cognition
WILTON, Conn., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Elemental Cognition, the artificial intelligence company founded and led by Dr. David Ferrucci, creator of IBM’s Watson, and funded to date by global...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx Presents Data Demonstrating Positive Activity of NYX-458 on Cognitive Performance and Biomarkers in a Preclinical Model of Head Injury
21 août 2019 08h33 HE | Aptinyx Inc.
EVANSTON, Ill., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx Reports Second Quarter 2019 Financial Results and Highlights
12 août 2019 06h33 HE | Aptinyx Inc.
Reported that NYX-2925 met primary and secondary endpoints in Phase 2 fibromyalgia study On track to initiate three additional Phase 2 studies in 2H 2019 across pipeline of CNS product candidates ...
Minerva logo
Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in Schizophrenia
17 mai 2018 08h00 HE | Minerva Neurosciences, Inc
WALTHAM, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Cogstate Establishes
Cogstate Establishes Rare Disease and Pediatric Center of Excellence
05 avr. 2018 09h16 HE | Cogstate Ltd.
New Haven, CT, April 05, 2018 (GLOBE NEWSWIRE) -- The cognitive science company, Cogstate Ltd (ASX.CGS) today announced the establishment of a Rare Disease and Pediatric Center of Excellence to lead...
Neuronascent Appoints New Board Member
12 avr. 2017 06h30 HE | Neuronascent, Inc.
CLARKSVILLE, MD--(Marketwired - April 12, 2017) - Neuronascent, Inc., a neuro-pharmaceutical company developing proprietary therapeutics for Alzheimer's disease, Parkinson's disease, and psychiatric...